Integra Lifesciences Holdings (IART) Capital Expenditures (2009 - 2026)

Integra Lifesciences Holdings' Capital Expenditures history runs 18 years deep, the most recent figure standing at $14.8 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 48.66% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $67.4 million (down 42.85% YoY), while the FY2025 annual figure was $81.4 million, down 22.01% from the prior year.
• Capital Expenditures came in at $14.8 million for Q1 2026 at Integra Lifesciences Holdings, down from $17.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $29.7 million in Q2 2024 to a low of $9.2 million in Q3 2022.
• A 5-year average of $18.2 million and a median of $15.5 million in 2024 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures jumped 126.69% in 2024 and slumped 48.88% in 2025, its largest moves.
• Integra Lifesciences Holdings' Capital Expenditures stood at $14.5 million in 2022, then jumped by 69.72% to $24.5 million in 2023, then gained by 20.64% to $29.6 million in 2024, then plunged by 41.84% to $17.2 million in 2025, then retreated by 13.74% to $14.8 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $14.8 million, $17.2 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison